Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis

Journal of Immunology

Volumn 183, Issue 7, 2009, Pages 4371-4377

  Chiron, David ^a   Pellat Deceunynck, Catherine ^a   Maillasson, Mike ^a,b   Bataille, Régis ^a   Jego, Gaëtan ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b Parc Scientifique de Luminy   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; LEXATUMUMAB; MAPATUMUMAB; NUCLEASE; PHOSPHOROTHIOIC ACID; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND DR4 RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND DR5 RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; LIGAND; OLIGODEOXYRIBONUCLEOTIDE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; TLR9 PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; COLON CANCER; CONTROLLED STUDY; CYTOLYSIS; DRUG BINDING; DRUG INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; BIOSYNTHESIS; BREAST TUMOR; COLON TUMOR; CPG ISLAND; FEMALE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CPG ISLANDS; FEMALE; HUMANS; LIGANDS; MULTIPLE MYELOMA; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOLL-LIKE RECEPTOR 9;

EID: 70449719357     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901436     Document Type: Article

References (37)

1. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801.
2. Haas, T., J. Metzger, F. Schmitz, A. Heit, T. Muller, E. Latz, and H. Wagner. 2008. The DNA sugar backbone 2′ deoxyribose determines Toll-like receptor 9 activation. Immunity 28: 315-323.
3. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
4. Marshak-Rothstein, A. 2006. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6: 823-835. (Pubitemid 44631651)
5. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995. (Pubitemid 41057715)
6. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20: 709-760.
7. Gilliet, M., W. Cao, and Y. J. Liu. 2008. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8: 594-606.
8. Chiron, D., I. Bekeredjian-Ding, C. Pellat-Deceunynck, R. Bataille, and G. Jego. 2008. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 112: 2205-2213.
9. Krieg, A. M. 2008. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27: 161-167.
10. Huang, B., J. Zhao, J. C. Unkeless, Z. H. Feng, and H. Xiong. 2008. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27: 218-224.
11. Jego, G., R. Bataille, A. Geffroy-Luseau, G. Descamps, and C. Pellat-Deceunynck. 2006. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 20: 1130-1137. (Pubitemid 43797308)
12. Bohnhorst, J., T. Rasmussen, S. H. Moen, M. Flottum, L. Knudsen, M. Borset, T. Espevik, and A. Sundan. 2006. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 20: 1138-1144. (Pubitemid 43797309)
13. Longo, P. G., L. Laurenti, S. Gobessi, A. Petlickovski, M. Pelosi, P. Chiusolo, S. Sica, G. Leone, and D. G. Efremov. 2007. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 21: 110-120.
14. Yu, L., and S. Chen. 2008. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol. Immunother. 57: 1271-1278.
15. Chiron, D., C. Pellat-Deceunynck, M. Amiot, R. Bataille, and G. Jego. 2009. TLR3 ligand induces NF-κB activation and various fates of multiple myeloma cells depending on IFN-α production. J. Immunol. 182: 4471-4478.
16. Hideshima, T., D. Chauhan, P. Richardson, C. Mitsiades, N. Mitsiades, T. Hayashi, N. Munshi, L. Dang, A. Castro, V. Palombella, et al. 2002. NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem. 277: 16639-16647.
17. Romagnoli, M., G. Desplanques, S. Maiga, S. Legouill, M. Dreano, R. Bataille, and S. Barille-Nion. 2007. Canonical nuclear factor κB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin. Cancer Res. 13: 6010-6018.
18. Johnstone, R. W., A. J. Frew, and M. J. Smyth. 2008. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8: 782-798.
19. Terme, M., E. Ullrich, N. F. Delahaye, N. Chaput, and L. Zitvogel. 2008. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 9: 486-494.
20. Shankar, E., U. Sivaprasad, and A. Basu. 2008. Protein kinase Cε confers resistance of MCF-7 cells to TRAIL by Akt-dependent activation of Hdm2 and downregulation of p53. Oncogene 27: 3957-3966.
21. Soderstrom, T. S., M. Poukkula, T. H. Holmstrom, K. M. Heiskanen, and J. E. Eriksson. 2002. Mitogen-activated protein kinase/extracellular signal-regulated kinase signaling in activated T cells abrogates TRAIL-induced apoptosis upstream of the mitochondrial amplification loop and caspase-8. J. Immunol. 169: 2851-2860.
22. + B cells. J. Immunol. 181: 8267-8277.
23. Osawa, Y., S. Iho, R. Takauji, H. Takatsuka, S. Yamamoto, T. Takahashi, S. Horiguchi, Y. Urasaki, T. Matsuki, and S. Fujieda. 2006. Collaborative action of NF-κB and p38 MAPK is involved in CpG DNA-induced IFN-α and chemokine production in human plasmacytoid dendritic cells. J. Immunol. 177: 4841-4852.
24. Liu, J., A. Hamrouni, D. Wolowiec, V. Coiteux, K. Kuliczkowski, D. Hetuin, A. Saudemont, and B. Quesnel. 2007. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110: 296-304.
25. Clemenceau, B., G. Gallot, R. Vivien, J. Gaschet, M. Campone, and H. Vie. 2006. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy. J. Immunother. 29: 53-60. (Pubitemid 43756081)
26. Pukac, L., P. Kanakaraj, R. Humphreys, R. Alderson, M. Bloom, C. Sung, T. Riccobene, R. Johnson, M. Fiscella, A. Mahoney, et al. 2005. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer 92: 1430-1441.
27. Menoret, E., P. Gomez-Bougie, A. Geffroy-Luseau, S. Daniels, P. Moreau, S. Le Gouill, J. L. Harousseau, R. Bataille, M. Amiot, and C. Pellat-Deceunynck. 2006. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 108: 1346-1352.
28. Kohlhaas, S. L., A. Craxton, X. M. Sun, M. J. Pinkoski, and G. M. Cohen. 2007. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J. Biol. Chem. 282: 12831-12841. (Pubitemid 47100635)
29. Wagner, H. 2008. The sweetness of the DNA backbone drives Toll-like receptor 9. Curr. Opin. Immunol. 20: 396-400.
30. He, W., Q. Liu, L. Wang, W. Chen, N. Li, and X. Cao. 2007. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol. Immunol. 44: 2850-2859. (Pubitemid 46412506)
31. Fennewald, S. M., and R. F. Rando. 1995. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J. Biol. Chem. 270: 21718-21721.
32. Guvakova, M. A., L. A. Yakubov, I. Vlodavsky, J. L. Tonkinson, and C. A. Stein. 1995. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270: 2620-2627.
33. Schlaepfer, E., A. Audige, B. von Beust, V. Manolova, M. Weber, H. Joller, M. F. Bachmann, T. M. Kundig, and R. F. Speck. 2004. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J. Virol. 78: 12344-12354. (Pubitemid 39458753)
34. Vaillant, A., J. M. Juteau, H. Lu, S. Liu, C. Lackman-Smith, R. Ptak, and S. Jiang. 2006. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrob. Agents Chemother. 50: 1393-1401.
35. Luganini, A., P. Caposio, S. Landolfo, and G. Gribaudo. 2008. Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry. Antimicrob. Agents Chemother. 52: 1111-1120. (Pubitemid 351358395)
36. Matsumura, T., Z. Hu, T. Kato, M. Dreux, Y. Y. Zhang, M. Imamura, N. Higara, J. M. Juteau, F. L. Cosset, K. Chayama, A. Vaillant, and T. J. Liang. 2009. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 137: 673-681.
37. Bishop, J. S., J. K. Guy-Caffey, J. O. Ojwang, S. R. Smith, M. E. Hogan, P. A. Cossum, R. F. Rando, and N. Chaudhary. 1996. Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. J. Biol. Chem. 271: 5698-5703.